First approval for Daiichi Sankyo's long-acting flu drug, in Japan
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has received the first approval worldwide, in Japan, for the long-acting neuraminidase inhibitor, laninamivir, which it will market as Inavir.